Home > Site map > Report overview

Nanotechnology in Medical Applications: The Global Market

Published by: BCC Research

Published: Jan. 17, 2012 - 187 Pages

CHAPTER ONE: INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR DOING THE STUDY; SCOPE OF REPORT; MARKET ANALYSES AND FORECASTS; METHODOLOGY; INTENDED AUDIENCE; INFORMATION SOURCES; ANALYST CREDENTIALS; RELATED BCC REPORTS; BCC ON-LINE SERVICES; DISCLAIMER; DISCLAIMER (CONTINUED)
CHAPTER TWO: SUMMARY: DEFINITION; RESEARCH AND COMMERCIALIZATION; APPLICATIONS; DRUG DELIVERY; DRUGS AND THERAPY; IN VIVO IMAGING; IN VITRO DIAGNOSTICS; BIOMATERIALS; ACTIVE IMPLANTS; MARKET; SUMMARY TABLE NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, THROUGH 2016 ($ BILLIONS); SUMMARY FIGURE NANOMEDICAL GLOBAL SALES BY THERAPEUTIC AREA, 2009-2016 ($ BILLIONS)
CHAPTER THREE: OVERVIEW: MEDICAL NANOTECHNOLOGY: NANOMEDICINE; FUTURE POSSIBILITIES; MARKET POTENTIAL; ABOUT NANOTECHNOLOGY; ABOUT NANOTECHNOLOGY (CONTINUED); THE MANY USES OF NANOTECHNOLOGY; MEDICAL APPLICATIONS; ENVIRONMENTAL APPLICATIONS; MILITARY APPLICATIONS; COSMETICS; APPLICATIONS IN DEVELOPMENT; THE TOOLS OF NANOTECHNOLOGY; C60/FULLERENES; CARBON NANOTUBES; NANOPARTICLES; NANOWIRES; MOLECULAR NANOTECHNOLOGY; RISKS OF NANOTECHNOLOGY; POISON/TOXICITY; NANOTECHNOLOGY IN THE MARKETPLACE; NANOTECHNOLOGY IN THE … (CONTINUED); NANOTECHNOLOGY IN THE … (CONTINUED)
CHAPTER FOUR: NANOMEDICINE: DEVELOPMENT OF NANOMEDICAL TECHNOLOGIES; LIPOSOMES; Liposomes (Continued); DENDRIMERS; NANOCRYSTALS; MICELLES; FULLERENES; POLYMERIC NANOPARTICLES; NANOPARTICLE-DRUG CONJUGATES; LEGEND-TARGETED NANOPARTICLES; CERAMIC NANOPARTICLES; VIROSOME NANOPARTICLES; THERAPEUTIC USES OF NANOMEDICINE; CANCER DIAGNOSTICS AND THERAPY; DRUG DELIVERY; DIAGNOSTIC TOOLS; VARIOUS THERAPEUTIC TARGETS AND TECHNOLOGIES; FUTURE TRENDS AND RESEARCH POSSIBILITIES; FUNDAMENTAL NANOTECHNOLOGY RESEARCH; THE RISK FACTOR; THE RISK FACTOR (CONTINUED)
CHAPTER FIVE: MARKETS FOR NANOMEDICINE: MARKETS FOR NANOMEDICINE; MARKET DRIVERS; MARKET ESTIMATES AND FORECASTS; GLOBAL NANOMEDICINE MARKET; MAIN PRODUCT CATEGORIES; DRUG DELIVERY; MOLECULAR DIAGNOSTICS; MARKET ANALYSIS BY CLINICAL APPLICATION; Cancer; CNS Disorders; Infection; Cardiovascular and Autoimmune Disorders; REGIONAL AND NATIONAL MARKET ANALYSIS; U.S.; Japan; Europe
CHAPTER SIX: THE NANOMEDICINE INDUSTRY: ABLYNX; ABRAXIS BIOSCIENCE; ABRAXIS BIOSCIENCE (CONTINUED); ACCESS; NANOPARTICLE NETWORK DELIVERY; TARGETED NANOPARTICLE DELIVERY; ACRYMED INC.; ACRYMED INC. (CONTINUED); ACUSPHERE; ADVANCED MAGNETICS; ALLTRACELL; ALPHARX INC.; ALPHARX INC. (CONTINUED); ANSON NANO-BIOTECHNOLOGY (ZHUHAI) CO. LTD; APHIOS CORP.; PROTEIN NANOPARTICLES; POLYMER NANOSPHERES; PHOSPHOLIPID NANOSOMES; BIOCRYSTAL LTD; BIOFORCE NANOSCIENCES; THE VIRICHIP VIRUS DETECTION PLATFORM; BIO-GATE; MEDICAL APPLICATIONS; BIOPHAGE PHARMA; PHAGES; BIOPHAN TECHNOLOGIES; BIOSANTÉ PHARMACEUTICALS INC.; NOVEL VACCINE ADJUVANT: BIOVANT; THERAPEUTIC DRUG DELIVERY PLATFORM: BIOAIR/BIOORAL; CALANDO PHARMACEUTICALS; CAMURUS AB; CAPSULUTION PHARMA AG; DRUG DELIVERY SYSTEMS; CERULEAN; COMBIMATRIX CORPORATION; DRUG DEVELOPMENT; DAMAGE PREVENTION CONCEPT; ELAN DRUG TECHNOLOGIES; ELAN DRUG TECHNOLOGIES (CONTINUED); ENZON PHARMACEUTICALS, INC.; PEG TECHNOLOGY; PEGYLATION CUSTOMIZED LINKER TECHNOLOGY; PEG PRO-DRUG TRANSPORT TECHNOLOGY; FARFIELD SCIENTIFIC; GE HEALTHCARE LIFE SCIENCES; GILEAD; NANO-LIPOSOMES; HEALTHPLUS INTERNATIONAL INC.; IGI INC.; JR NANOTECH, PLC; KEREOS, INC.; KEYSTONE NANO, INC.; NANOJACKETS; NANOLIPOSOMES; KLEINDIEK NANOTECHNIK GMBH; NANOWORKSTATION; LABOPHARM INC.; LABOPHARM INC. (CONTINUED); LIPLASOME PHARMA A/S; LUMERA CORPORATION; NANOCAPTURE MICROARRAYS; MAGFORCE NANOTECHNOLOGIES AG; MAGFORCE NANOTECHNOLOGIES AG (CONTINUED); MAGNAMEDICS GMBH; DIAGNOSTICS; MAGCUSTOM: CUSTOMIZED NANO- AND MICROPARTICLES; EFFICIENT AND LOW-COST DIAGNOSTICS; MULTIFUNCTIONAL DRUG CARRIER; MICROFLUIDICS INTERNATIONAL CORPORATION; MIV THERAPEUTICS INC.; CARDIOVASCULAR HEART STENTS; MOLECULAR PROFILES; MOLECULAR PROFILES (CONTINUED); NANOBIO CORPORATION; NANOBIO CORPORATION (CONTINUED); NANOBIO CORPORATION (CONTINUED); NANOBIOTIX; NANOBIOTIX (CONTINUED); NANOCARRIER CO LTD; NANOCARRIER CO LTD (CONTINUED); NANOCYTE INC; NANOGEN INC; ELECTRONIC MICROARRAY; INSTRUMENTATION; Molecular Biology Workstation; Molecular Biology Workstation Cartridge; NanoChip 400 System; NANOINK, INC.; NANOINK, INC. (CONTINUED); NANOLOGIX, INC.; NANOMED PHARMACEUTICALS, INC.; NANOMIX INC; NANOPHARM AG; NANOSPECTRA BIOSCIENCES, INC; NANOSPECTRA BIOSCIENCES, INC. (CONTINUED); NANOSPHERE, INC.; NANOSTRUCTURES, INC.; NANOSYN INC; NANOSYN INC (CONTINUED); NANOTHERAPEUTICS, INC.; NANOTHERAPEUTICS, INC. (CONTINUED); NANOTROPE INC.; NANOVIRICIDES INC; FLUCIDE-I; NUCRYST PHARMACEUTICALS; NUTRALEASE; ORTHOVITA INC.; PIONEER SURGICAL TECHNOLOGY; PSIVIDA LTD; QIAGEN N.V.; SKYEPHARMA PLC; SOLID LIPID NANOPARTICLES (SLNS): SOLID SOLUTIONS OF DRUGS IN A LIPID MATRIX.; DISSOCUBES; SOLUBEST; SOLUBEST (CONTINUED); STARPHARMA HOLDINGS LTD; DENDRIMER NANOTECHNOLOGY; TECAN GROUP LTD.; TELOMOLECULAR CORPORATION; TELOMOLECULAR CORPORATION (CONTINUED); TELOMOLECULAR CORPORATION (CONTINUED); TELOMOLECULAR CORPORATION (CONTINUED)
APPENDIX: TABLE 27 GLOSSARY; TABLE 27 (CONTINUED); TABLE 27 (CONTINUED); TABLE 27 (CONTINUED)

Abstract

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for prescription drug products incorporating nanotechnology features. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2016; these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the nanomedicine-related drug market. The wider economic environment is also taken into account.

The report examines strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive market.

REASONS FOR DOING THE STUDY

Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine has already produced a number of significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies and look to its future.

SCOPE OF REPORT

This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry is discussed with profiles of the leading 60+ companies, including recent M&A activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

Get full details about this report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Nanotechnology in Medical Applications: The Global Market

Table of Contents

Abstract

US: 800.298.5699

Int'l: +1.240.747.3093